GlassScriptPhysician profile
Leo Lane
NPI 1770570426
$10,802.97
in general payments reported to CMS, 2019-2025
42 companies · $1,389 in 2025
The $1,389 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,625 · 2020: $1,130 · 2021: $1,561 · 2022: $1,752 · 2023: $1,632 · 2024: $1,714 · 2025: $1,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,734.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,286.58 | 2020-2025 | |
| Pfizer INC. | $771.90 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $673.45 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $657.89 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $643.83 | 2019-2025 | Jardiance, Spiriva Respimat |
| Lilly USA, LLC | $590.65 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $533.98 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $437.45 | 2019-2024 | Myrbetriq, Veozah |
| Amgen INC. | $345.08 | 2019-2024 | Repatha, Otezla, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $329.74 | 2019-2022 | |
| Amarin Pharma, INC. | $318.31 | 2019-2022 | |
| Abbott Laboratories | $317.88 | 2021-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $296.37 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $199.77 | 2019-2024 | Belsomra, Gardasil, Gardasil 9 |
| Exact Sciences Corporation | $195.94 | 2023-2024 | Cologuard Collection Kit |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leo Lane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.